Excerpts from recent editorials in the United States and abroad: July 15 The Washington Post on access to birth control after the SCOTUS ruling on abortion: The French company that has asked for permission to sell birth control pills over the counter in the United States says the timing of its request to the Food and Drug Administration, coming soon after the Supreme Court’s decision overturning Roe v. Wade, is coincidental. That might be, but the court’s decision eliminating the constitutional right to abortion makes more urgent than ever the imperative of easily accessible birth control. As with any drug, the FDA must follow the science. But if over-the-counter birth control makes sense — and for years it has worked safely in other countries — the agency should approve it as soon as possible. Paris-based HRA Pharma announced last week that it has applied to the FDA for approval to switch Opill, a progestin-only daily oral contraceptive licensed for prescription use in 1973, to...
from ABC News: US https://ift.tt/pbVt5NE
via IFTTT
No comments:
Post a Comment